NO20042035L - Forbedret anvendelse av antitumorforbindelse i kreftterapi - Google Patents
Forbedret anvendelse av antitumorforbindelse i kreftterapiInfo
- Publication number
- NO20042035L NO20042035L NO20042035A NO20042035A NO20042035L NO 20042035 L NO20042035 L NO 20042035L NO 20042035 A NO20042035 A NO 20042035A NO 20042035 A NO20042035 A NO 20042035A NO 20042035 L NO20042035 L NO 20042035L
- Authority
- NO
- Norway
- Prior art keywords
- cancer therapy
- improved use
- antitumor compound
- antitumor
- compound
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
- A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4995—Pyrazines or piperazines forming part of bridged ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/243—Platinum; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Inorganic Chemistry (AREA)
- Molecular Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Accommodation For Nursing Or Treatment Tables (AREA)
- Medical Preparation Storing Or Oral Administration Devices (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US34841401P | 2001-10-19 | 2001-10-19 | |
| PCT/US2002/033548 WO2003039571A1 (en) | 2001-10-19 | 2002-10-21 | Improved use of antitumoral compound in cancer therapy |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NO20042035L true NO20042035L (no) | 2004-05-18 |
Family
ID=23367939
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO20042035A NO20042035L (no) | 2001-10-19 | 2004-05-18 | Forbedret anvendelse av antitumorforbindelse i kreftterapi |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US20050004018A1 (pl) |
| EP (1) | EP1435988A4 (pl) |
| JP (1) | JP2005509650A (pl) |
| KR (1) | KR20050038578A (pl) |
| CN (1) | CN1606449A (pl) |
| AU (1) | AU2002343548B2 (pl) |
| BR (1) | BR0213424A (pl) |
| CA (1) | CA2462502A1 (pl) |
| HU (1) | HUP0401903A3 (pl) |
| IL (1) | IL161430A0 (pl) |
| MX (1) | MXPA04003674A (pl) |
| NO (1) | NO20042035L (pl) |
| PL (1) | PL368458A1 (pl) |
| RU (1) | RU2306933C2 (pl) |
| WO (1) | WO2003039571A1 (pl) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MY164077A (en) * | 1999-05-13 | 2017-11-30 | Pharma Mar Sa | Compositions and uses of et743 for treating cancer |
| MXPA02011319A (es) | 2000-05-15 | 2003-06-06 | Pharma Mar Sa | Analogos antitumorales de ecteinascidina 743. |
| BR0115162A (pt) * | 2000-11-06 | 2003-10-21 | Pharma Mar Sa | Tratamentos antitumorais eficazes |
| GB0117402D0 (en) * | 2001-07-17 | 2001-09-05 | Pharma Mar Sa | New antitumoral derivatives of et-743 |
| GB0202544D0 (en) | 2002-02-04 | 2002-03-20 | Pharma Mar Sa | The synthesis of naturally occuring ecteinascidins and related compounds |
| GB0312407D0 (en) * | 2003-05-29 | 2003-07-02 | Pharma Mar Sau | Treatment |
| HRP20080598T3 (en) | 2003-11-13 | 2009-01-31 | Pharma Mar | Combination of et-743 with 5-fluorouracil pro-drugs for the treatment of cancer |
| AU2004291037A1 (en) * | 2003-11-14 | 2005-06-02 | Pharma Mar, S.A. | Combination therapy comprising the use of ET-743 and paclitaxel for treating cancer |
| GB0326486D0 (en) * | 2003-11-14 | 2003-12-17 | Pharma Mar Sau | Combination treatment |
| WO2006005602A2 (en) * | 2004-07-09 | 2006-01-19 | Pharma Mar, S.A. | Use of ecteinascidin in the treatment of cancer in patients with low level of brca1 |
| EP1827500B1 (en) * | 2004-10-26 | 2009-05-06 | Pharma Mar S.A., Sociedad Unipersonal | Pegylated liposomal doxorubicin in combination with ecteinescidin 743 |
| ATE368461T1 (de) | 2004-10-29 | 2007-08-15 | Pharma Mar Sa | Zusammensetzungen enthaltend ecteinascidin und einen disaccharide |
| GB0522082D0 (en) * | 2005-10-31 | 2005-12-07 | Pharma Mar Sa | Formulations |
| CA2652035A1 (en) * | 2006-05-12 | 2007-11-22 | Pharma Mar, S.A. | Anticancer treatments |
| KR101598229B1 (ko) | 2007-02-16 | 2016-02-26 | 메리맥 파마슈티컬즈, 인크. | Ｅｒｂｂ3에 대한 항체 및 이의 용도 |
| US20100267732A1 (en) * | 2007-10-19 | 2010-10-21 | Pharma Mar, S.A. | Prognostic Molecular Markers for ET-743 Treatment |
| WO2010019952A2 (en) * | 2008-08-15 | 2010-02-18 | Merrimack Pharmaceuticals, Inc. | Methods, systems and products for predicting response of tumor cells to a therapeutic agent and treating a patient according to the predicted response |
| KR101798679B1 (ko) | 2010-03-11 | 2017-11-16 | 메리맥 파마슈티컬즈, 인크. | ３중 음성 및 기저형 유방암 치료 시의 ｅｒｂｂ３ 저해제의 용도 |
| RU2631597C2 (ru) | 2011-07-15 | 2017-09-25 | Нусерт Сайенсиз, Инк. | Композиции и способы модулирования метаболических путей |
| GB201217439D0 (en) * | 2012-09-28 | 2012-11-14 | Topotarget As | Combination therapy |
| SG10201709195TA (en) | 2012-11-13 | 2017-12-28 | Nusirt Sciences Inc | Compositions and methods for increasing energy metabolism |
| EP3087394A2 (en) | 2013-12-27 | 2016-11-02 | Merrimack Pharmaceuticals, Inc. | Biomarker profiles for predicting outcomes of cancer therapy with erbb3 inhibitors and/or chemotherapies |
| US10184006B2 (en) | 2015-06-04 | 2019-01-22 | Merrimack Pharmaceuticals, Inc. | Biomarkers for predicting outcomes of cancer therapy with ErbB3 inhibitors |
| KR102491180B1 (ko) | 2017-04-27 | 2023-01-20 | 파르마 마르 에스.에이. | 항종양 화합물 |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5089273A (en) * | 1986-06-09 | 1992-02-18 | Board Of Trustees Of The University Of Illinois | Ecteinascidins 729, 743, 745, 759A, 759B and 770 |
| US5256663A (en) * | 1986-06-09 | 1993-10-26 | The Board Of Trustees Of The University Of Illinois | Compositions comprising ecteinascidins and a method of treating herpes simplex virus infections therewith |
| FR2697752B1 (fr) * | 1992-11-10 | 1995-04-14 | Rhone Poulenc Rorer Sa | Compositions antitumorales contenant des dérivés du taxane. |
| US5428040A (en) * | 1993-08-31 | 1995-06-27 | The Du Pont Merck Pharmaceutical Company | Carbocyclic fused-ring quinolinecarboxylic acids useful as immunosuppressive agents |
| US5478932A (en) * | 1993-12-02 | 1995-12-26 | The Board Of Trustees Of The University Of Illinois | Ecteinascidins |
| US20040059112A1 (en) * | 1994-02-18 | 2004-03-25 | Rinehart Kenneth L. | Ecteinascidins |
| MY164077A (en) * | 1999-05-13 | 2017-11-30 | Pharma Mar Sa | Compositions and uses of et743 for treating cancer |
| AR035842A1 (es) * | 1999-05-14 | 2004-07-21 | Pharma Mar Sa | Metodo de hemisintesis para la formacion de compuestos intermediarios y derivados y de estructuras relacionadas con la ecteinascidina y de tetrahidroisoquinolinfenoles y compuestos intermediarios de aplicacion en dicho metodo |
| CZ302498B6 (cs) * | 1999-11-15 | 2011-06-15 | Pharma Mar, S. A. | Farmaceutický prípravek obsahující aplidin pro lécení rakovinových onemocnení |
| WO2001077115A1 (en) * | 2000-04-12 | 2001-10-18 | Pharma Mar, S.A. | Antitumoral ecteinascidin derivatives |
| BR0115162A (pt) * | 2000-11-06 | 2003-10-21 | Pharma Mar Sa | Tratamentos antitumorais eficazes |
| GB0312407D0 (en) * | 2003-05-29 | 2003-07-02 | Pharma Mar Sau | Treatment |
| GB0324201D0 (en) * | 2003-10-15 | 2003-11-19 | Pharma Mar Sau | Improved antitumoral combinations |
| GB0326486D0 (en) * | 2003-11-14 | 2003-12-17 | Pharma Mar Sau | Combination treatment |
| ATE368461T1 (de) * | 2004-10-29 | 2007-08-15 | Pharma Mar Sa | Zusammensetzungen enthaltend ecteinascidin und einen disaccharide |
-
2002
- 2002-10-21 PL PL02368458A patent/PL368458A1/pl not_active Application Discontinuation
- 2002-10-21 BR BR0213424-1A patent/BR0213424A/pt not_active IP Right Cessation
- 2002-10-21 AU AU2002343548A patent/AU2002343548B2/en not_active Ceased
- 2002-10-21 IL IL16143002A patent/IL161430A0/xx unknown
- 2002-10-21 EP EP02780496A patent/EP1435988A4/en not_active Withdrawn
- 2002-10-21 HU HU0401903A patent/HUP0401903A3/hu unknown
- 2002-10-21 KR KR1020047005765A patent/KR20050038578A/ko not_active Ceased
- 2002-10-21 CA CA002462502A patent/CA2462502A1/en not_active Abandoned
- 2002-10-21 US US10/492,320 patent/US20050004018A1/en not_active Abandoned
- 2002-10-21 RU RU2004115110/14A patent/RU2306933C2/ru not_active IP Right Cessation
- 2002-10-21 CN CNA028256662A patent/CN1606449A/zh active Pending
- 2002-10-21 JP JP2003541862A patent/JP2005509650A/ja active Pending
- 2002-10-21 WO PCT/US2002/033548 patent/WO2003039571A1/en not_active Ceased
- 2002-10-21 MX MXPA04003674A patent/MXPA04003674A/es not_active Application Discontinuation
-
2004
- 2004-05-18 NO NO20042035A patent/NO20042035L/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| HUP0401903A3 (en) | 2008-07-28 |
| PL368458A1 (pl) | 2005-03-21 |
| WO2003039571A1 (en) | 2003-05-15 |
| MXPA04003674A (es) | 2004-07-23 |
| RU2306933C2 (ru) | 2007-09-27 |
| HUP0401903A2 (hu) | 2005-01-28 |
| RU2004115110A (ru) | 2005-03-10 |
| BR0213424A (pt) | 2004-12-14 |
| IL161430A0 (en) | 2004-09-27 |
| AU2002343548B8 (en) | 2003-05-19 |
| US20050004018A1 (en) | 2005-01-06 |
| KR20050038578A (ko) | 2005-04-27 |
| CA2462502A1 (en) | 2003-05-15 |
| JP2005509650A (ja) | 2005-04-14 |
| EP1435988A1 (en) | 2004-07-14 |
| CN1606449A (zh) | 2005-04-13 |
| AU2002343548B2 (en) | 2007-11-08 |
| EP1435988A4 (en) | 2008-01-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO20042035L (no) | Forbedret anvendelse av antitumorforbindelse i kreftterapi | |
| CY2019030I2 (el) | Παραγωγο ραπαμυκινης για την θεραπευτικη αντιμετωπιση του καρκινου του πνευμονα | |
| IL169594A0 (en) | Treatment of cancer with 2-deoxyglucose | |
| PL370029A1 (pl) | Pochodne 2-amino-4-heteroaryloaminopirymidyny do stosowania w leczeniu raka | |
| EP1311262A4 (en) | CANCER THERAPY THROUGH COMBINATION THERAPY | |
| AU6048201A (en) | Quinazoline derivatives for the treatment of tumours | |
| IL164599A0 (en) | Combination therapy for the treatment of cancer | |
| EP1392818A4 (en) | FOR THE TREATMENT OF CANCER DISEASES IN HUMAN CERTAIN IMMUNE RECEPTOR | |
| IS6891A (is) | Aðferðir við gjöf epóþílon hliðstæðna við meðferðkrabbameins | |
| NO20034780D0 (no) | Antiangiogenisk kombinasjonsterapi for behandling av kreft | |
| HUP0500424A3 (en) | Combination therapy for the treatment of cancer | |
| AU2003212634A8 (en) | Compounds useful in the treatment of cancer | |
| IL161059A0 (en) | Substituted benzimidazole compounds and their use for the treatment of cancer | |
| EE200200479A (et) | Eksemestaani kasutamine rinnavähi ravis | |
| IL160722A0 (en) | Aryloxypropylamines as chemosensitizing agents in the treatment of cancer | |
| NO20014228L (no) | Radioaktiv cisplatin i behandling av cancer | |
| AU2003231803A8 (en) | Treatment of cancer with mefloquire | |
| GB0226595D0 (en) | Cancer therapy determination | |
| GB0329416D0 (en) | Treatment of cancer | |
| EP1463511A4 (en) | COMBINATORY ANTICANCER THERAPY | |
| NO20042850L (no) | Kreftbehandling | |
| GB0129451D0 (en) | Treatment of cancer | |
| GB0125764D0 (en) | Diagnosis of cervicasl cancer | |
| AU2003217925A1 (en) | Treatment of metastatic institute for cancer | |
| GB0008161D0 (en) | Treatment of cancer |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC2A | Withdrawal, rejection or dismissal of laid open patent application |